Abstract 1950
Background
Leukemia Inhibitory Factor (LIF) is a pleiotropic cytokine, highly expressed in a subset of tumors and correlates with poor prognosis. LIF is hypothesized to contribute to tumor microenvironment (TME) immunosuppression and regulation of cancer initiating cells. MSC-1 is a first-in-class humanized IgG1 monoclonal antibody that potently and selectively inhibits LIF. MSC-1 decreased tumor growth in mouse tumor models and generated durable regressions when combined with anti-PD-1.
Methods
Eligible pts had advanced relapsed/refractory solid tumors (regardless of pretreatment LIF tumor levels). The study employed an accelerated 3 + 3 escalation design to explore safety, dose-limiting toxicities (DLTs), preliminary efficacy, and define a recommended phase II dose (RP2D). Pts received treatment with MSC-1 intravenously (75mg-1500 mg) once every 3-weeks until disease progression. The three highest dose cohorts were expanded to further assess safety, PK, LIF peripheral target engagement, and to assess immuno-regulatory tumor activity in paired pre- and on treatment tumor tissue.
Results
Dose escalation enrollment was completed on March 6, 2019 with 41 pts (14 in dose escalation; 27 in expanded cohorts). There were no DLTs. As of April 26, 2019, there were 38 AEs (30 grade (Gr) 1,7 Gr 2, and 1 Gr 3), reported as possibly related to MSC-1 (fatigue in 10 pts and nausea in 4 pts were the most common). Overall PK profile was linear with estimated terminal half-life of ∼17 days and a benign anti-drug antibody profile. There was evidence of durable peripheral LIF saturation at higher doses or after multiple doses. Stable disease (≥ 16 weeks) was noted in 7 pts. Comparison of paired pretreatment and on treatment biopsies in the 1125mg expanded cohort, showed at least one mechanism-based change in all 4 evaluable patients, and in the two patients continuing therapy beyond 16 weeks, evidence of reversal of TME immunosuppression through infiltration of CD8 T cells and changes in macrophage populations.
Conclusions
MSC-1 holds promise as an anti-cancer therapy and should be readily combinable with other agents. Updated safety, efficacy, PK, LIF stabilization analyses, and paired tumor biopsy data will be presented.
Clinical trial identification
NCT03490669.
Editorial acknowledgement
Legal entity responsible for the study
Northern Biologics Inc.
Funding
Northern Biologics, Inc.
Disclosure
E. Borazanci: Speaker Bureau / Expert testimony: Ipsen; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Fujifilm; Advisory / Consultancy: Concept; Research grant / Funding (institution): Northern Biologics; Research grant / Funding (institution): Minneamrita; Research grant / Funding (institution): Fujifilm; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Bioline; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Ambry; Research grant / Funding (institution): Mabvax. A. Schram: Research grant / Funding (institution): Northern Biologics. I. Brana: Research grant / Funding (institution): Northern Biologics; Advisory / Consultancy, Research grant / Funding (self): Orion Pharmac; Speaker Bureau / Expert testimony, Research grant / Funding (self): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck Serono; Research grant / Funding (self): Celgene; Research grant / Funding (self): Gliknik; Research grant / Funding (self): GSK; Research grant / Funding (self): Jannsen; Research grant / Funding (self): Kura; Research grant / Funding (self): MSD; Research grant / Funding (self): Novartis; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche. M. Vieito Villar: Research grant / Funding (institution): Northern Biologics. E. Garralda: Research grant / Funding (institution): Northern Biologics; Advisory / Consultancy, Research grant / Funding (self): Roche Genentech Inc; Advisory / Consultancy: Ellipses Pharma; Advisory / Consultancy: Neomed Therapeutics1 Inc; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Janssen Global Services; Speaker Bureau / Expert testimony: BMS; Research grant / Funding (self), Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Glycotope ; Research grant / Funding (self), Travel / Accommodation / Expenses: Menarini; Research grant / Funding (self): Novartis; Leadership role: ESMO; Research grant / Funding (self): Principia Biopharma Inc; Research grant / Funding (self): Lilly, S.A ; Research grant / Funding (self): Loxo Oncology Inc ; Research grant / Funding (self): Symphogen A/S ; Research grant / Funding (self): Incyte; Research grant / Funding (self): Pharma Mar; Research grant / Funding (self): MacroGenics; Research grant / Funding (self): Kura Oncology,Glycotope, Pierre Fabre, Blueprint Medicines , Beigene, Sierra Oncology, Genmab. A. Spreafico: Research grant / Funding (institution): Northern Biologics. M. Oliva: Research grant / Funding (institution): Northern Biologics. N. Lakhani: Research grant / Funding (institution): ALX Oncology; Research grant / Funding (institution): Forty Seven Inc; Research grant / Funding (institution): INhibRx; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Arqule; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): Livzon; Research grant / Funding (institution): Ascentage; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Northern Biologics; Research grant / Funding (institution): Apexian; Research grant / Funding (institution): Asana Biosciences; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Formation Biologics/Forbius; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Constellation Pharma,; Research grant / Funding (institution): TaiRx, CytomX, Coordination Pharma, Symphogen, Cerulean, Jounce Therapeutics. R. Wasserman: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Northern Biologics. K. Hoffman: Shareholder / Stockholder / Stock options, Full / Part-time employment: Northern Biologics. R. Hallett: Shareholder / Stockholder / Stock options, Full / Part-time employment: Northern Biologics. J. Anido: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Northern Biologics. P. Giblin: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Northern Biologics. N. Pandya: Shareholder / Stockholder / Stock options: Northern Biologics. A. Kelly: Advisory / Consultancy: Northern Biologics. J. Seoane: Advisory / Consultancy, Research grant / Funding (self), Shareholder / Stockholder / Stock options, Officer / Board of Directors: Northern Biologics; Research grant / Funding (self): Mosaic Biomedicals; Research grant / Funding (self): Roche-Glycart. D.D. Von Hoff: Research grant / Funding (institution): Northern Biologics; Advisory / Consultancy, Research grant / Funding (institution): Celgene. L.L. Siu: Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca/MedImmune; Advisory / Consultancy: Morphosys; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy: GeneSeeq; Advisory / Consultancy: Loxo; Advisory / Consultancy: Oncorus; Advisory / Consultancy, Research grant / Funding (institution): Symphogen; Advisory / Consultancy: Seattle Genetics; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (self): GlaxoSmithKine; Research grant / Funding (institution): Karyopharm; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Northern Biologics, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks; Spouse / Financial dependant: Agios. D.M. Hyman: Advisory / Consultancy, Travel / Accommodation / Expenses: Chugai Pharma; Advisory / Consultancy: CytomX Therapeutics; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Bayer Pharmaceuticals; Advisory / Consultancy, Travel / Accommodation / Expenses: Genentech / Roche; Research grant / Funding (self): Loxo Oncology; Research grant / Funding (self): PUMA Biotechnology; Research grant / Funding (self): Bayer Pharmaceuticals; Research grant / Funding (institution): Northern Biologics. J. Tabernero: Advisory / Consultancy: Array Biopharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Beigene; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Chugai; Advisory / Consultancy: Genentech, Inc; Advisory / Consultancy: Genmab, A/S; Advisory / Consultancy: Halozyme; Advisory / Consultancy: Imugene Limited; Advisory / Consultancy: Inflection Biosciences Limite; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Kura Oncology; Advisory / Consultancy: MSD; Advisory / Consultancy: Menarini; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Merrimack; Advisory / Consultancy: Merus; Advisory / Consultancy: Molecular Partners; Advisory / Consultancy: Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen; Research grant / Funding (institution): Northern Biologics, Symphogen A/S, Servier SL, Roche Farma SA, Pharma Mar, Novartis Farmacéutica SA, Amgen, Debiopharm International SA, Janssen-Cilag SA, Mologen AG; Leadership role: ESMO.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract